在XenoAptamers与目标蛋白质中,第五个字母,疏水性非自然基的严格相互作用
Michiko Kimoto1, Hui Pen Tan1, Ken-Ichiro Matsunaga1
1Xenolis Pte. Ltd., 85 Science Park Drive, #02-05B, The Cavendish, Singapore 118259, Singapore.
Journal of the American Chemical Society
|September 7, 2023
概括
研究人员通过修改非自然基来优化XenoAptamers. 新变体Ys和Bs显著增强了XenoAptamer与标蛋白的结合亲和力,显示出特定的分子内相互作用.
科学领域:
- 生物化学和分子生物学
- 合成生物学
- 生物技术
背景情况:
- 异胺是含有非自然基的DNA异胺,用于增强蛋白质结合.
- 疏水性UB7-(2-thienyl) imidazo[4,5-b]pyridine (Ds) 增加了XenoAptamer的亲和力,但其最佳结构尚不清楚.
- Ds最初是基于PCR的aptamer生成与一个补充的UB,Px.
研究的目的:
- 在XenoAptamers中优化第五个字母 (疏水性UB) 的配体结构.
- 研究Ds结构修改对XenoAptamer亲属性的影响.
- 识别改善XenoAptamer与标蛋白质结合的新型UB变体.
主要方法:
- 合成了13种Ds非自然基的变体.
- 包含这些Ds变体的XenoAptamers的生成.
- 使用结合试验对改性XenoAptamers的亲和性评估.
主要成果:
- Ds的微妙结构变化显著改变了XenoAptamer的亲和力.
- 含有4- 2- 乙烯 (Ys) 或4- 2- 乙烯 (Bs) 的XenoAptamers显著改善了向蛋白的亲属性.
- Ys和Bs是Ds变体,其中一个原子被一个碳原子取代.
结论:
- UBs与目标蛋白之间的结合相互作用是特定的分子内相互作用,而不仅仅是疏水接触.
- UBs的结构优化是一种成熟的XenoAptamer亲和力的可行策略.
- Ys和Bs代表了开发高亲和力XenoAptamers的有希望的非自然基.
相关概念视频
DNA Base Pairing
27.5K
Erwin Chargaff’s rules on DNA equivalence paved the way for the discovery of base pairing in DNA. Chargaff’s rules state that in a double-stranded DNA molecule,
27.5K
Ligand Binding Sites
12.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.9K
Transfer RNA Synthesis
12.0K
One of the unique features of tRNA is the presence of modified bases. In some tRNAs, modified bases account for nearly 20% of the total bases in the molecule. Altogether, these unusual bases protect the tRNA from enzymatic degradation by RNases.
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
12.0K
Drug-Receptor Bonds
2.9K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.9K
Targets for Drug Action: Overview
6.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.4K


